Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Tetsuya
T
Tanimoto
Akiko
A
Hori
Masahiro
M
Kami
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005938:Glucocorticoids / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000037:antagonists & inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D005938:Glucocorticoids; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; C511774:sipuleucel-T